CD19 antibody

Catalog No. ABIN6941100

The Mouse Monoclonal anti-CD19 antibody has been validated for FACS, WB, IF, ELISA and Coat. It is suitable to detect CD19 in samples from Human, Monkey and Chimpanzee.

Quick Overview for CD19 antibody (ABIN6941100)

Target: CD19 (CD19 Molecule (CD19))

Reactivity: Human, Monkey, Chimpanzee

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD19 antibody is un-conjugated

Application: Flow Cytometry (FACS), Western Blotting (WB), Immunofluorescence (IF), ELISA, Coating (Coat)

Clone: PDR134

Product Details anti-CD19 Antibody

Purification: Purified by Protein A/G

Immunogen: Pokeweek-stimulated Daudi and Raji cells

Isotype: IgM kappa

Application Details

Application Notes:

Positive Control: Tonsil, Lymph Node or Spleen.

Known Application: ELISA (For coating, order antibody without BSA), Flow Cytometry (1-2 μg/million cells), Immunofluorescence (0.5-1 μg/mL), Western Blot (1-2 μg/mL)Optimal dilution for a specific application should be determined.

Restrictions: For Research Use only

Handling

Concentration: 200 μg/mL

Buffer: 10 mM PBS with 0.05 % BSA & 0.05 % azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-80 °C

Storage Comment: Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Expiry Date: 24 months

Target Details for CD19

Target: CD19 (CD19 Molecule (CD19))

Alternative Name: CD19

Background: CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.

Molecular Weight: 95kDa

Gene ID: 930

UniProt: P15391

Pathways: Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway